@article{826bd377470449a39008f23ed3a422a1,
title = "Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil",
abstract = "BACKGROUND: Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy. PATIENTS AND METHODS: A phase II study examining chronomodulated XELOX(30) (XELOX(30chron)): oxaliplatin: 130 mg/m(2) on day 1, as a 30-min infusion between 1 and 3 p.m. Capecitabine: total daily dose of 2000 mg/m(2), 20% of the dose between 7 and 9 a.m. and 80% of the dose between 6 and 8 p.m. in patients with mCRC resistant to irinotecan. Seventy-one patients were enrolled. Response rate was 18%; median progression-free survival 5.1 months and median overall survival (OS) 10.2 months. Platelet count and performance status were significantly correlated to OS in multivariate analyses. Neurotoxicity grade 2 and 3 was seen in 25% and 2% of patients, respectively, other grade 3 toxic effects were as follows: nausea 6%, vomiting 3%, diarrhoea 12% (3% experienced grade 4) and palmoplantart erytem 9%. CONCLUSION: XELOX(30chron) is a convenient second-line regimen with efficacy and safety profile similar to other oxaliplatin schedules. To further investigate chronomodulated XELOX, we have started a Nordic randomised phase II study comparing XELOX(30) and XELOX(30chron) as first-line therapy in patients with mCRC.",
keywords = "Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Chronotherapy, Colorectal Neoplasms, Deoxycytidine, Female, Fluorouracil, Humans, Male, Middle Aged, Treatment Failure, Treatment Outcome",
author = "C Qvortrup and M Yilmaz and D Ogreid and A Berglund and L Balteskard and J Ploen and T Fokstuen and H Starkhammar and H S{\o}rbye and K Tveit and P Pfeiffer",
year = "2008",
doi = "10.1093/annonc/mdn002",
language = "English",
volume = "19",
pages = "1154--9",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
}